Mark L Levitt, MD
RedHill Biopharma Limited
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mark L Levitt, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:50 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04502069 · Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring OxygenRedHill Biopharma Limited · withdrawn · COVID-19, Lung Infection · study director
- Ph2/Ph3NCT04467840 · Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 PneumoniaRedHill Biopharma Limited · completed · COVID-19, Lung Infection · study director
- Ph2NCT04414618 · A Study of Opaganib in Coronavirus Disease 2019 PneumoniaRedHill Biopharma Limited · completed · Coronavirus Infections · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.